详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

Li, Xiaoxin[1,8] * ; Dai, Hong[2,13] ; Li, Xiaorong[3,16] ; Han, Mei[4,17] ; Li, Jun[5,12,33] ; Suhner, Andrea[6] ; Lin, Renxin ; Wolf, Sebastian[7] ; Li, Xiaoxin[1,8] ; Qi, Huijun[8] ; Tao, Ye[8] ; Li, Yan[8] ; Bai, Yujing[8] ; Yin, Hong[8] ; Liu, Guodong[8] ; Han, Li[8] ; Qian, Tong[8] ; Huang, Lvzhen[8] ; Miao, Heng[8] ; Zhao, Mingwei[8] ; Hou, Jing[8] ; Cheng, Yong[8] ; Liang, Jianhong[8] ; Shi, Xuan[8] ; Qu, Jinfeng[8] ; Yu, Wenzhen[8] ; Tao, Yong[8] ; Chen, Yi[8] ; Zhang, Feng[9] ; Shi, Xuehui[9] ; Gao, Liqin[9] ; Ding, Ning[9] ; Yang, Lihong[9] ; Zhao, Shiqiang[9] ; Yang, Qiong[9] ; Shen, Rong[9] ; Xiong, Ying[9] ; Dong, Fangtian[10] ; Zhang, Xiao[10] ; Gong, Di[10] ; Qu, Yi[10] ; Dai, Fangfang[10] ; He, Feng[10] ; Han, Xiaoxu[10] ; Dai, Rongping[10] ; Du, Hong[10] ; Yu, Weihong[10] ; Li, Donghui[10] ; Yang, Zhikun[10] ; Ma, Zhizhong[11] ; Zhang, Min[11] ; Dou, Hongliang[11] ; Chen, Xiuhong[11] ; Chu, Ying[11] ; Ren, Jing[11] ; Qian, Fang[11] ; Yang, Fan[11] ; Zhao, Lin[11] ; Ding, Aihua[11] ; Guo, Tong[11] ; Lu, Xinrong[11] ; Liu, Yuling[11] ; Wang, Xin[11] ; Yang, Liu[12] ; Li, Jun[5,12,33] ; Zhu, Ruilin[12] ; Hao, Jianchen[12] ; Qiao, Lijun[12] ; Guo, Chunying[12] ; Zhang, Jing[12] ; Nie, Hongping[12] ; Gu, Xiaopeng[12] ; Du, Lixiao[12] ; Zhang, Yadi[12] ; Zhang, Wenbo[12] ; Zhang, Shijie[12] ; Hao, Jianchen[12] ; Zhao, Liang[12] ; Shi, Jingmei[12] ; Wu, Hailong[12] ; Dai, Hong[2,13] ; Huang, Jianfeng[13] ; Zhao, Jing[13] ; Hu, Lei[13] ; Yu, Xiaobing[13] ; Lu, Yingyi[13] ; Peng, Nuan[13] ; Gu, Xiaoya[13] ; Long, Li[13] ; Shi, Zian[13] ; Wang, Yanling[14]

; Zhao, Lu[14]

; Zhang, Xiaolei[14]

; Hou, Yanli[14]

; Huang, Yinxiang[14] ; Li, Mingming[14]

; Zhang, Fan[14] ; Hong, Hui[14]

; Wang, Kang[14]

; Tang, Simeng[14]

; Liu, Dachuan[15] ; Junjie, Bian[15] ; lei, Zhang[15] ; Dai, Weijia[15] ; Huiqing, Yang[15] ; Ning, Hao[15] ; Wang, Xizhe[15] ; Zhao, Liyan[15] ; Li, Xiaorong[3,16] ; Wang, Shaorui[16] ; Wang, Linni[16] ; Han, Jindong[16] ; Chen, Lu[16] ; Ma, Jinghua[16] ; Ma, He[16] ; Li, Zhiqing[16] ; Wang, Tingting[16] ; Yu, Rongguo[16] ; Dong, Xiaojun[16] ; Li, Ying[16] ; Guo, Junlin[16] ; Hu, Yahan[16] ; Sheng, Xueyong[16] ; Li, Shuang[16] ; Han, Mei[4,17] ; Cong, Chunxia[17] ; Li, Li[17] ; Han, Ying[17] ; Xu, Yanshan[17] ; Ma, Nannan[17] ; Xie, Shiyong[17] ; Lu, Lin[18] ; Hu, Andina[18] ; Lian, Ping[18] ; Ma, Wei[18] ; Su, Guangxing[18] ; Yuan, Miner[18] ; Lai, Wangying[18] ; Li, Xiaofang[18] ; Chen, Guangxian[18] ; Yu, Xiling[18] ; Mai, Guiying[18] ; Zhong, Junying[18] ; Chen, Xing[18] ; Liu, Bingqian[18] ; Liu, Yuhong[18] ; Zhao, Xiujuan[18] ; Mo, Qinmei[18] ; Cheng, Jiangmei[18] ; Yang, Hui[18] ; Yang, Qiufen[18] ; Zhong, Xiaojing[18] ; Jin, Chenjin[18] ; He, Caiqing[18] ; Xie, Qiuhua[18] ; Huang, Ping[18] ; Mai, Xiaoxi[18] ; Zhong, Jingxiang[19] ; Zhang, Xiaoming[19] ; Liu, Xiaoyong[19] ; Zhang, Ting[19] ; Zhang, Liqiong[19] ; Wang, Guifang[19] ; He, Xiaojuan[19] ; Meng, Jing[19] ; Zhang, Rijia[19] ; Tian, Yuan[19] ; Chen, Weiqi[20] ; Chen, Shirong[20] ; Huang, Bingrong[20] ; Zhang, Guihua[20] ; Zhang, Anlin[20] ; Liu, Xinyu[20] ; Zheng, Kangkeng[20] ; Zhou, Lingling[20] ; Chen, Haoyu[20] ; Peng, Kun[20] ; Zhou, Zhaotao[20] ; Lin, Dusheng[20] ; Huang, Huichun[20] ; Lin, Xiaoang[20] ; Zhang, Junjun[21,22] ; Zhang, Meixia[21,22] ; Zhu, Helian[21,22] ; Huang, Xi[21,22] ; Xin, Mei[21,22] ; Zeng, Zhibing[21,22] ; Meng, Dan[21,22] ; Wu, Ye[21,22] ; Wu, Qianying[21,22] ; Ma, Lin[21,22] ; Lai, Zhifeng[21,22] ; Gao, Sheng[21,22] ; Wang, Xiaoyue[21,22] ; Ren, Juqin[21,22] ; Qiu, Guoxian[21,22] ; Ye, Jian[24] ; Liao, Hongxia ; Tang, Ying ; Tao, Lusha ; Liu, Shaozhang ; Yue, Li ; Feng, Sijia ; Xu, Jie ; Dong, Yan ; Tan, Nian ; Chen, Yanli ; Chen, Shaoqiong ; Zhao, Peiquan[23] ; Wang, Zhaoyang[23] ; Dong, Yang[23] ; Man, Xiaofei[23] ; Ji, Xunda[23] ; Tian, Tian[23] ; Feng, Huazhang[23] ; Li, Xin[23] ; Huang, Qiujing[23] ; Wang, Shiyuan[23] ; Cai, Kebo[23] ; Zhang, Qi[23] ; Li, Yian[23] ; Jin, Haiying[23] ; Sun, Xiaodong[24] ; Zheng, Kairong[24] ; Feng, Jingyang[24] ; Ye, Liang[24] ; Shih, Alice[24] ; Liu, Xiaoxiao[24] ; Cai, Zhengyuan[24] ; Wu, Ying[24] ; Fan, Ying[24] ; He, Ping[24] ; Xie, Liping[24] ; Sun, Jian[24] ; Duan, Zhongju[24] ; Zhao, Tingting[24] ; Wang, Weijun[24] ; Cheng, Lu[24] ; Yao, Pang[24] ; Wu, Zhifeng[25] ; Xu, Huiyan[25] ; Zhang, Jie[25] ; Zhu, Dongyuan[25] ; Meng, Xiaomei[25] ; Fu, Yuting[25] ; Chen, Tiantian[25] ; Lu, Shui[25] ; Zou, Wenjun[25] ; Shen, Ye[26] ; Tong, Jianping[26] ; Yu, Chengying[26] ; Lu, Hong[26] ; Wu, Qin[26] ; Fan, Wenting[26] ; Huang, Baishuang[26] ; Wang, Xiaoen[26] ; Hong, Nan[26] ; Wu, Miaoqin[27] ; Li, Xiaoxia[27,1] ; Zheng, Qingqing[27] ; Chen, Yurong[27] ; Xu, Hong[27] ; Liu, Hui[27] ; Liu, Zhe[27] ; Shen, Ting[27] ; Guo, Hong[27] ; Zhang, Luyi[27] ; Chi, Xinchang[27] ; Zhao, Hailan[27] ; Yu, Jie[27] ; Zhang, Lan[27] ; Song, Yanping[28,29,30,31,32,33,34,35] ; Ding, Qin[28] ; Qiu, Jinlan[28] ; Liu, Yan[28,35] ; Dong, Yangting[28] ; Chang, Feng[28] ; Chen, Zhongshan[28] ; Chen, Yunhui[28] ; Yan, Ming[28] ; Huang, Zhen[28] ; Huang, Zhijian[28] ; Ma, Lina[28] ; Du, Qian[28] ; Zhang, Mingchang[29] ; Li, Pengcheng[29] ; Yan, Wenhui[29] ; Zheng, Hai[29] ; Xu, Kangkang[29] ; Fang, Jing[29] ; Wei, Jingjing[29] ; Yang, Junjie[29] ; Sheng, Shuangyan[29] ; Ao, Qiong[29] ; Liu, Xiaoling[30] ; Ge, Lina[30] ; Zhou, Tingye[30] ; Zhu, Qianqian[30] ; Lin, Bing[30] ; Luo, Yingdong[30] ; Huang, Ying[30] ; Zeng, Leilei[30] ; Zheng, Weiwei[30] ; Yan, Miaojun[30] ; Sun, Zuhua[30] ; Wang, Yusheng[31] ; Zhang, Peng[31] ; Wang, Haiyan[31] ; Zhu, Jinting[31] ; Yu, Xiaoni[31] ; Li, Manhong[31] ; Wang, Qihua[31] ; Li, Juan[31] ; Bai, Wenle[31] ; Hou, Huiyuan[31] ; Zhang, Zifeng[31] ; He, Jin[31] ; Sun, Dongjie[31] ; Song, Xiaojin[31] ; Tang, Luosheng[32] ; Zhao, Fei[32] ; Zhang, Kun[32] ; Ouyang, Pingbo[32] ; Zeng, Jun[32] ; Liu, Jia[32] ; Wei, Wei[32] ; Tian, Jiao[32] ; Xu, Haifeng[33] ; Li, Jun[5,12,33] ; Xu, Jing[33] ; Wang, Min[33] ; Shi, Depeng[33] ; Wu, Peipei[33] ; Sun, Dawei[34] ; Shi, Liping[34] ; Jiang, Bo[34] ; Cheng, Fang[34] ; Jia, Danhua[34] ; Zhang, Zhongyu[34] ; Zhou, Xuemei[34] ; Song, Wulian[34] ; Shen, Ling[34] ; Fan, Pan[34] ; Yi, Jinglin[35] ; Yang, Haijun[35] ; Zuo, Yanping[35] ; Zeng, Jiao[35] ; Liu, Yan[28,35] ; Du, Hongyan[35] ; Yu, Li[35] ; Liu, Xian[35] ; Wan, Shenghui[35] ; Zhu, Si[35] ; Li, Qiulin[35] ; Dong, Wenjia[35] ;

单位： [1]Peking Univ Peoples Hosp, Dept Ophthalmol, 11 Xi Zhi Men South Ave, Beijing 100044, Peoples R China [2]Beijing Hosp, Dept Ophthalmol, Natl Ctr Gerontol, Beijing, Peoples R China [3]Tianjin Med Univ Eye Hosp, Tianjin, Peoples R China [4]Tianjin Eye Hosp, Tianjin, Peoples R China [5]Novartis Pharma AG, Basel, Switzerland [6]China Novartis Inst BioMed Res Co Ltd, Shanghai, Peoples R China [7]Univ Hosp Bern, Univ Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland [8]Peking Univ Peoples Hosp, Beijing 100044, Beijing, Peoples R China [9]Beijing Tongren Hosptial, Beijing 100176, Beijing, Peoples R China [10]Hosp Beijing, Peking Union Med Coll, Beijing 100730, Peoples R China [11]Peking Univ Third Hosp, Beijing 100191, Beijing, Peoples R China [12]Peking Univ First Hosp, Beijing 100034, Beijing, Peoples R China [13]Beijing Hosp, Beijing 100730, Beijing, Peoples R China [14]Friendship Hosp, Beijing 100050, Beijing, Peoples R China [15]Beijing Univ, Xuan Wu Hosp Capital Med, Beijing 100053, Peoples R China [16]Tianjin Med Univ Eye Hosp, Tianjin 300020, Tianjin, Peoples R China [17]Tianjin Eye Hosp, Tianjin 300070, Tianjin, Peoples R China [18]Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China [19]First Affiliated Hosp Jinan Univ Guangzhou, Guangzhou 510632, Guangdong, Peoples R China [20]Shantou Univ, Shantou Int Eye Ctr, Shantou 515041, Guangdong, Peoples R China [21]Sichuan Univ, West China Hosp, Chengdu 610041, Sichuan, Peoples R China [22]Third Mil Med Univ Daping Hos, 3 Hosp, Chongqing 400042, Chongqing, Peoples R China [23]Shanghai XinHua Hosp Shanghai, Shanghai 200092, Peoples R China [24]Shanghai Gen Hosp, Shanghai 200080, Shanghai, Peoples R China [25]Wuxi 2 Peoples Hosp, Wuxi, Jiangsu, Peoples R China [26]Zhejiang Univ, First Affiliated Hosp, Hangzhou 310003, Zhejiang, Peoples R China [27]Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China [28]Wuhan Gen Hosp Guangzhou Mil, Wuhan 430070, Hubei, Peoples R China [29]Wuhan Union Hosp, Wuhan 430022, Hubei, Peoples R China [30]Wenzhou Med Univ, Affiliated Eye Hosp, Wenzhou 325027, Zhejiang, Peoples R China [31]First Affiliated Hosp Fourth Mil Med Xian, Xian 710032, Shaanxi, Peoples R China [32]Second Xiangya Hosp Cent South Univ, Changsha 410011, Hunan, Peoples R China [33]Qingdao Eye Hosp, Qingdao, Shandong, Peoples R China [34]2 Affiliated Hosp Harbin Med Univ, Harbin 150086, Heilongjiang, Peoples R China [35]Affiliated Eye Hosp Nanchang Univ, Nanchang 330019, Jiangxi, Peoples R China

出处：

DOI：

ISSN：

关键词： Anti-vascular endothelial growth factor Diabetic macular edema Pro re nata Ranibizumab

摘要：

PurposeTo demonstrate the efficacy and safety of ranibizumab 0.5mg pro re nata (PRN) versus laser photocoagulation for the treatment of Chinese patients with visual impairment due to diabetic macular edema (DME).MethodsREFINE was a phase III, 12-month, double-masked, multicenter, laser-controlled study in patients (aged 18years) with DME. Patients were randomized 4:1 to receive either ranibizumab 0.5mg or laser dosing regimen. Efficacy was evaluated as mean average change in best-corrected visual acuity (BCVA) from Months 1 to 12 versus baseline (primary endpoint), anatomical outcomes, treatment exposure, and safety were also assessed.ResultsRanibizumab was statistically superior (p<0.001) to laser treatment, with a mean average BCVA gain of 6.8 letters (ranibizumab) over 12months versus 1.1 letters (laser). At Month 12, mean BCVA gain was 7.8 letters (ranibizumab) and 2.5 letters (laser) from baseline. Patients in the ranibizumab arm received a mean number of 7.9 intravitreal injections, whereas those in the laser arm received a mean of 2.1 treatments. There were no new safety signals.ConclusionRanibizumab 0.5mg PRN demonstrated a statistically significant and clinically meaningful treatment effect versus laser and was well tolerated in Chinese patients with visual impairment due to DME over 12months.

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 3 区眼科学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区眼科学

JCR分区：

出版当年[2017]版：

Q2 OPHTHALMOLOGY

最新[2023]版：

Q2 OPHTHALMOLOGY

影响因子： 最新[2023版] 2.4 最新五年平均[2021-2025] 2.7 出版当年[2017版] 2.249 出版当年五年平均[2013-2017] 2.23 出版前一年[2016版] 2.349 出版后一年[2018版] 2.25

第一作者：

第一作者单位： [1]Peking Univ Peoples Hosp, Dept Ophthalmol, 11 Xi Zhi Men South Ave, Beijing 100044, Peoples R China [8]Peking Univ Peoples Hosp, Beijing 100044, Beijing, Peoples R China

通讯作者：

通讯机构： [1]Peking Univ Peoples Hosp, Dept Ophthalmol, 11 Xi Zhi Men South Ave, Beijing 100044, Peoples R China [8]Peking Univ Peoples Hosp, Beijing 100044, Beijing, Peoples R China [27]Zhejiang Prov Peoples Hosp, Hangzhou, Zhejiang, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study

文献详情

相关文献